Market Access

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

Rahul Mittal explains how execution infrastructure can help generics manufacturers improve hospital access, reduce delays, and strengthen coordination.

The expansion of TrumpRx will increase price transparency and purchase options of generic drugs for cash-paying patients.

Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

For drugs already on the market, there may be little companies can do to limit business impact; however, for new development drugs, there are some critical considerations.

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare disease market and adds a portfolio of neuromuscular and neurological therapies.

In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing pharmaceutical pricing and forecasting.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Charley Maxwell explains why Annex 21 is not just a regulatory hurdle, but a key commercial risk point.

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.

Manasi Salgaonkar examines how accurate class of trade research enables precise pricing, contract eligibility, and compliance.